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In the recent past, there has been a rise in Prostate Cancer (PCa) in Asia, 
particularly India.  Although systematic reviews on PCa have dealt on the 
genetics, genomics and the environmental influence in causal of PCa, no 
predictive analytics in comparing the PCa from Caucasian, American to Asian 
population was attempted. In this review article, we have attempted to elaborate 
this aspect of PCa and deliberated on challenges related to next generation 
sequencing methods of PCa’s manifestation when compared to the west. Keyword: 
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1. Background 
Concern for the global epidemiology of Prostate cancer (PCa) is substantially growing [1] as it 
accounts to the second most common cancer worldwide [2,3] and third most prevalent cancer in India [4].  PCa 
cases are diagnosed in over one million annually and the mortality rate has grown to more than 300,000 deaths 
per year. Incidence and mortality differ among geographic regions and populations showing multifactorial 
impacts of genetic variation, diet, lifestyle, environmental factors and use of prostate specific antigen-based 
screening policies [5]. In 2012, 1.1 million men were diagnosed with PCa worldwide, a total of 759,000 cases 
were recorded, (Figure 1) with Europe having the highest estimate of PCa cases (37.8%) followed by Northern 
America (28.4%), Asia (15.8%), Latin America and Caribbean (11.5%), Africa (4.0%) and Oceania (2.4%) [2].  
Reported PCa incidence rates varied over 25-fold worldwide [6], even as many men not coming forward for the 
diagnosis itself. On the other hand, the Prostate-specific Antigen (PSA) screening serves as one of the most 
common non-invasive biomarkers to detect PCa[7]. As described by Chen et al. 2017, the world mortality-to-
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incidence ratios (MIR) for PCa was 28.1% wherein less developed regions demonstrated high MIR for PCa with 
the highest MIR of 71.9% found in Africa. Countries with higher levels of human development and per capita 
gross domestic product (GDP) had been accounted with higher PCa incidence but not in mortality rates. In 
addition, the PCa incidence and mortality correlation with socio-economic development of country showed a 
simple linear regression between PCa incidence/mortality and human development index (HDI) [6]. On the 
other hand, Asians who immigrated to the western countries have been accounted for higher incidence of PCa 
when compared to the people in their native country. Reason for the higher occurrence of the PCa among Asian 
migrants could be due to different health care systems and more importantly the diet [8]. Therefore, it can be 
speculated that the westernized diet in Asian countries may have an influence on high risk of PCa, however it 
has been difficult to prove the relationship [9].  
 
Figure 1. Estimated five year prevalence of PCa cases (*1000), adult population. Source:  
GLOBOCAN, 2012. 
 
1.1. PCa in India and South Asian Population 
The census of India which released on July 15, 2011 revealed interesting statistics relevant to the 
pattern of prevalence and other disease characteristics of PCa[10]. Though the prevalence and characteristics of 
PCa have been studied in India, its true incidence is limited, perhaps owing to the lack of exposure of patients to 
clinic and the unavailability of cancer registries. In the recent past, the population of India has displayed rapid 
changes in lifestyles, dietary practices and socio-economic milieu which have resulted in an enormous increase 
in the number of cancer cases. The most recent Population Based Cancer Registries (PBCRs) of different cities 
for the time period (2008–2011) shows that PCa has ranked among top ten leading sites of cancer in many cities 
including Bangalore, Barshi, Bhopal, Chennai, Delhi, Mumbai, Kamrup, Ahmedabad, Kolkata, Kollam, Nagpur, 
Pune, Trivandrum and Wardha (Figure 2). There are some reports which illustrate several genetic mutations and 
polymorphism of certain genes (for egGSTM1 and GSTP1) associated with PCa[11]. Interestingly, higher 
prevalence of polymorphisms in DNA repair systems XRCC1 and XPD, is responsible for DNA repair which 
could lower cancer susceptibility, has been reported in south asian populations. 
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Figure 2.Graph showing trends over time in age adjusted rates for five population-based cancer 
registries.  Image adapted from Jain et al. 2014. The incidence of PCa is relatively low in some states like Gujrat 
(Ahmedabad and Wardha PBRCs) and Madhya Pradesh (Bhopal PBCR) with  the  lowest being north east 
region of India [12]. 
 
1.2. Identifying PCa mutations using Next Generation sequencing methods 
In the recent past, next generation sequencing (NGS) has allowed the simultaneous identification of 
millions of short stretches of nucleic acids [13] screening a large number of genes with greater sensitivity and 
cost effectiveness [14]. The NGS studies branched towards understanding the cancer genome of several tumor 
types [15]. An attempt to perform diagnostic, prognostic, predictive biomarkers and biomarker-designed clinical 
trials is on the anvil [14].  Application of NGS has led towards easier identification of the PCa variants by 
exposing hidden information through genomic and transcriptomics landscape, especially identifying key 
biological and molecular components of progression and potential therapeutic opportunities of castration-
resistant PCa (CRPC), a more advanced and metastatic form of PCa. [16].  CRPC was earlier known as 
hormone-refractory PC but different studies have shown that CRPC is not hormone-independent as androgen 
axis continues to play an important role in its growth.  
As far as mutations are concerned, structural genomic rearrangements [17] due to deletion of tumor 
suppressors such as PTEN, TP53, NKX3-1 [18], CDKN1B [19] and BRCA mutations identified in patients with 
PCa were found to be somatic while ca. 15% of patients were known to be associated with metastatic CRPC 
(mCRPC) [16]. The genome-wide profiling in the plasma of patients having PCa revealed multiple copy 
numbers, such as losses in 8p and gains in 8q in addition to identification of TMPRSS2-ERG rearrangement 
associated 3-Mbp deletion on chromosome 21 [20]. Thus, determining somatic copy number alterations (SCNA) 
serving as mutational hotspots could be helpful. A novel mutational hotspot at the KCCAT42, FENDRR, 
CAT1886 and STCAT2 loci at the 16q23.1-q24.3 loss were identified as alterations of lincRNA sequences [21]. 
Tomlins 2005described that, in approximately 50% of all PCas’ have gene fusions and rearrangements of ETS 
family of transcription factors (TMPRSS2-ERG). Moreover, other ETS family members such as TMPRSS2-
ETV1, TMPRSS2- ETV4, TMPRSS2-ETV5, and SLC45A3-ERG are frequently rearranged and over-expressed in 
PCa. This phenomenon is specifically found only in prostatic tumors but occasionally present in high-grade 
prostatic intraepithelial neoplasia.  
From in vitro and in vivo assessments of gene and protein expression, Ren et al. 2018 showed that the 
PLXNA1 protein as an effective therapeutic target to treat advanced PCa. Enhanced reduced representation 
bisulfite sequencing (ERRBS) can detect genome-wide DNA methylation at single-base resolution including 
CGI shores and allele-specific methylation (ASM) at various regions [24]. Based on the ChIP-Seq, Chen et al. 
2013 showed that ERG restores an androgen receptor (AR) transcriptome in PTEN-deleted PCa. In addition, by 
using methylated DNA immunoprecipitation sequencing (MeDIP-Seq) epigenetic mechanisms such as DNA 
methylation and histone modification can be studied which are known to play an important role in 
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PCadevelopment and progression associated with molecular and cellular alteration [26]. One of the most 
important DNA methylation markers which have been frequently reported in PCa is GSTP1 promoter 
hypermethylation, resulting in the loss of GSTP1 expression [27].  A number of methylation profiles have been 
developed and are being evaluated as potential markers for early diagnosis and risk assessment [25]. In the 
recent-past, an iCLIP-Seq method to infer RNA-Protein interactions at a higher resolution is made available 
[28]. 
 
1.3. Screening PCa using PSA 
Prostate Specific Antigen (PSA) has been widely used as a tumor marker for PCa detection albeit has 
become a bit controversial in use [29]. The PSA is a glycoprotein with enzymatic protease activity secreted by 
prostatic epithelium and due to its enzymatic activity; the PSA liquefies the semen and increases the sperm 
motility [30]. PSA is a serine protease of approximately 33 kDa in size and is secreted by epithelial cells of 
prostate. In normal prostate, PSA is secreted into the luminal fluid whereas in case of PCa, it gets leaked into 
circulation due to disruption of basal cell layer resulting in an increase in PSA level [31]. The drawback of PSA 
test is its low specificity since PSA levels can be elevated in benign prostatic hyperplasia (BPH), prostatic 
infarction and in prostatitis [32]. The other major drawback of PSA is that it does not differentiate between 
different stages of PCa[33]. To distinguish cancerous form from benign conditions and slow-growing from 
aggressive cancers,  there have been certain modifications in the current PSA test in the form of PSA density, 
PSA velocity, detection assays for checking molecular forms of PSA, and precursor or pro-PSA, human 
glandular kallikrein 2 (hK2) and urinary marker uPM3 which are in regular use. [34]. However, the most widely 
accepted screening method is the Gleason grading system, which predicts the cancer behavior. [35].  
 
1.4 Enhancement of the PSA tests 
Many efforts are being done to increase the diagnostic accuracy of PSA, including measurement of 
different molecular forms of PSA and rate of PSA increase. Total PSA (tPSA) refers to the sum of free PSA 
(unbound) and bound PSA (complexed predominantly to α-1-antichymotrypsin). The percentage free PSA test is 
approved for use in men which helps discriminate between the presence of PCa and BPH that serves as a 
predictor for biopsy [36]. In this process, laboratory tests in the form of Prostate Health Index (PHI), Digital 
Rectal Examination (DRE) have been helpful for primary screening the patients depending on the PSA test 
result [37]. 
 
 
2. Role of Metabolic diseases associated with PCa 
Metabolic diseases such as diabetes have a major role to play towards an increased risk of several 
human malignancies such as cancers of the pancreas, colon, endometrium, breast, kidney, liver, biliary tract and 
esophagus [38]. However, association of diabetes with decreased risk of PCa in depth only long-term diabetes 
has a protective effect on PCa have been reported from several studies [38,39]. There are several mechanisms to 
describe the protective effect of diabetes on PCa whereas protection against the PCa is due to the hormonal 
alterations; insulin and testosterone (T) in diabetes patients [40]. Initially insulin level of diabetes patients seems 
to be higher, then on decrease gradually with disease progression due to progressive beta cell burn out while T 
and sex hormones binding globulins (SHBG) levels also drop with the time [41]. Numerous human and animal 
studies have shown that both androgens [42] and insulin [43] have an effect on prostate cell growth and 
malignant transformation. Therefore, it is believed to be low risk of PCa is due to the decline of T and or insulin 
in patient with diabetes. However, the results of all the epidemiological studies rely on sex hormones not 
consistent [41]. Baradaran et al. 2009demonstrated that a small, albeit significant drop of PCa risk for increasing 
level of T/SHBG ratio  and further Will et al. in 1999 observed PCa risk to have doubled more than 5 years of 
diabetes diagnosis. However, steroids are not only the key factors for protective effect on PCa in diabetes 
patients but there could be an influence of hormonal environment also apart from testosterone, Insulin, insulin 
like growth factors (IGF) and leptin have effect on this inverse relationship [39]. Alterations in serum 
testosterone and IGF-I concentrations result by diabetes mellitus, have influence on PCa risk reduction among 
men with  genetic background of diabetes seems biologically plausible [45].  Another explanation based on the 
existence of a genetic factor that promotes diabetes risk and let fall the PCa risk. Genetic variation in 
peroxisome proliferator-activated receptor-gamma (PPARG) has association with a higher incidence of diabetes 
mellitus [46] and also expressed in human prostate adenocarcinomas and derived cell lines. Inhibition of PCa 
cell growth is expected to be the activation of this receptor with specific ligands [47]. As described by Hsing, 
Sakoda and Chua Jr., 2007 long term diabetes condition results in  insulin resistance. Insulin is a potent 
mitogenic and anti-apoptotic factor and stimulates the prostate growth further, DNA polymorphisms in the 
insulin gene may be linked with increased PCa risk. Progressive insulin resistance and B-cell failure along with 
insulin depletion arising with long-standing diabetes may limit insulin actions and reduce the PCa risk. 
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However, declined androgen levels in severe diabetes cases are probably due to a toxic effect of hyperglycemia 
on the leydig cells of the testis [49].  
The PCa incidence and mortality rates around the world show high correlation with average level of fat 
consumption. It is speculated that, western diet, rich in polyunsaturated fats, results in an increase in PCa cases. 
There have been several other studies associating effect of diet and certain essential nutrients on PCa risk but it 
could not be verified/confirmed [50]. On contrary, vegetarian diets such as fresh vegetables, polynutrients have 
shown a protective effect against PCa[10][50].. Furthermore, some natural spices and food additives used by 
south Asians play an important role in protection against cancer. For example, disease prevention capability of 
Turmeric has been widely discussed revealing its anti-oxidant, anti-inflammatory and chemo-preventive 
capacity which has been experimentally validated. The mechanism of action of turmeric involves blocking the 
activity of nuclear factor kappa-B (NF-kB), responsible for cancer cell survival in many cell types. On other 
hand, screening behavior and access to care are followed by south Asians are important in cancer prevention 
[10]. 
 
 
3. Genetic Biomarkers for PCa 
Urine, a waste product of kidney, has become one of the most attractive bio-fluids in clinical 
proteomics [51]. Urine is non-invasive, harmless and can be collected in large quantities without any significant 
proteolytic degradation [52,53]. Since prostate cells can be detected in urine [54], different biomarkers specific 
to PCa has been identified through urine and used as serological marker in diagnostic test, which are described 
below: 
 
3.1 Non-coding RNA as biomarkers 
MicroRNAs (miRNAs) are naturally-occurring, small (18-22 nucleotides) non-coding RNAs [55] that 
control the expression of more than 60% of protein-coding genes, have regulatory function on various molecular 
signaling pathways in the cell and are therefore potential diagnostic indicators of tumor formation and 
metastasis[56]. Differential expression of miRNA in PCa can be firmly correlated with its clinical expression 
suggesting that miRNAs are promising potential biomarkers and can be used in the detection of PCa[57].  At 
present, over 10000 human miRNAs have been reported out of which more than 200 common miRNAs have 
been analyzed from urine exosomes. There have been a large number of studies to prove the usefulness of 
urinary miRNAs in combination with clinical parameters for enhancing the accuracy of classification of PCa. 
Among all the miRNAs reported, miR-141, miR-21, miR-200b, miR221, miR-106b and miR-375 have been the 
most frequently investigated in urine from PCa patients[58][58,59]. Further analysis revealed that all these 
miRNAs were overexpressed in PCa serum samples compared with healthy controls which are in agreement 
with other studies. Together all these data suggest that use of miRNAs for non-invasive and specific detection of 
PCa can be very promising and can significantly improve the prediction level of the presence of PCa. 
Prostate cancer antigen 3 (PCA3), also known as Differential Display code 3 (DD3), a prostate-specific 
long non-coding RNA is dramatically overexpressed in human PCa tissue relative to normal prostate tissue [60]. 
The PCA3 score is calculated as the ratio of PCA3 to PSA mRNA (PCA3 mRNA/PSA mRNA x 1000) [61]. 
Compared to PSA test which gives false positives, PCA3 is more accurate in predicting clinically significant 
PCa and could be used as a diagnostic tool for PCa screening, grading and recurrence monitoring [62,63]. The 
limiting factor with PCA3 is that it does not correlate with Gleason score and clinical tumor staging which 
restricts its use in the medical field. Recent studies, however has enabled identification of other urinary long 
non-coding RNAs such as metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) a multiple 
cancer-associated lncRNA [64], and FR0348383, a PCa-associated lncRNA [65]. Whereas MALAT-1 or 
FR0348383 have great potential as independent predictors of PCa, a large multi-center study has validated the 
clinical utility of a 3 protein-coding gene panels (HOXC6, TDRD1, and DLX1) in urine [66]. Surprisingly, these 
three gene panels were known to have higher accuracy compared with urinary PCA3 or PSA in predicting 
aggressive PCa and combining them with PSA further improved the predictive accuracy.lncRNAs in plasma do 
not exist in their full-length form, though few stable fragments can be highly expressed and detectable in human 
plasma [67]. 
 
3.2. Gene fusion biomarkers 
Gene fusion is the process of combining two or more distinct genes into a single chimeric gene or 
transcript and a major mechanism in driving carcinogenesis [68]. The TMPRSS2-ERG fusion gene is a PCa-
specific fusion gene comprising androgen-related transmembrane protease serine 2 gene (TMPRSS2) and ETS-
related gene (ERG), which results in aberrant expression of the transcription factor ERG and inhibits normal 
prostate differentiation [69]. The diagnostic accuracy of combining TMPRSS2-ERG and PCA3 into a urine test 
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is significantly higher than that of the PSA test [70]. This combination can also reduce more than half of repeat 
biopsies with no notable negative consequences suggesting that a large number of men could avoid unnecessary 
invasive procedures by applying this approach [71]. 
A different approach was carried out by Liong group which can differentiate between PCa samples 
from normal samples by using blood-based microarray analysis [72]. Through quantitative real time PCR, a 
panel of seven genes (CTAM, CXCR3 (CD183), FCRL3, KIAA1143, KLF12, TMEM204, SAMSN1) were 
identified that could distinguish between aggressive PCa and healthy patients with a high sensitivity and 
specificity rate. All these significant genes have been shown to be involved in the immune response, chemotaxis 
and gene transcription regulation in carcinogenesis [73–75]. 
 
3.3. Gene methylation markers 
Gene methylation, a process by which methyl groups are added to DNA, represents an epigenetic 
alteration in PCa that has been well characterized in tissues and is a promising area for urine biomarker 
development [76]. In urine as well as tissue specimens, aberrant DNA methylation can be detected by a number 
of methods, viz. including methylation-specific polymerase chain reaction (MSP), methylation-sensitive single-
nucleotide primer extension (MS-SNuPE), bisulfite sequencing, and combined bisulfite restriction analysis 
(COBRA). One well-known DNA methylation target is glutathione-S-transferase P1 (GSTP1), a gene involved 
in phase II metabolism playing an important role in cell-cycle regulation. Expression of GSTP1 is high in the 
basal cell layer and luminal cells of benign prostate glands, with progressive loses observed in PIN with only the 
basal cell layer staining and is absent in PCa glands which underlines its involvement in early carcinogenesis 
[77]. Several studies have reported that measurement of GSTP1 promoter methylation may complement PSA 
screening for PCa diagnosis. Along with GSTP1, some other gene methylation markers (for e.g. APC, CRIP3, 
HOXD8) have also been tested which needs further evaluation to be used as a biomarker for PCa detection [78]. 
 
3.4. Protein based biomarkers 
Through proteomics studies, thousands of peptides can be analyzed simultaneously which leads to 
identification of new biomarkers. By using MALDI-TOF, a group identified two markers; uromodulin and 
semenogelin that shows high sensitivity and specificity and could distinguish PCa versus BPH. Engrailed -2 
(EN2), a protein found in the urine of patients with PCa, proved to be a potential biomarker for the diagnosis of 
PCa compared to ELISA [79]. Human kallikrein 2 (KLK2), a protease localized to prostatic epithelium, when 
used in combination with PSA, PCa diagnosis is significantly improved [80].  In addition, an olfactory Prostate-
specific G-protein-coupled receptor (PSGR) is known to activate major cell-survival signaling cascades causing 
an inhibition in PCa cell proliferation and might form a new subset of potential biomarker for the detection of 
PCa[81,82]. 
 
3.5. Immunological biomarkers 
One of the most widely used immunological biomarkers is alpha-methyl acyl-CoA Racemase 
(AMACR) which is highly expressed in prostate adenocarcinomas and can be detected in blood and urine with a 
high sensitivity and specificity [83,84]. B7-H3 (or CD276), an antigen-specific inhibitor of T-cell mediated anti-
tumoral immunity has been observed in high pathological stages of PCa[85,86]. Early prostate cancer antigen 
(EPCA), a nuclear matrix protein, have recently been shown to be involved in PCa which needs further 
evaluation [87]. 
 
 
4. Current challenges for diagnosis of Pca 
The significant factors related with PCa are PSA level, Gleason score, smaller prostate volume, 
abnormal DRE findings and, age besides ethnicity (National Collaborating Centre for Cancer (UK), 2008). Four 
third of all PCa patients are above 65 years old and it is rarely diagnosed in men under 50 [88]. The initial 
diagnosis date has been risen up approximately 5 years with the use of PSA testing [89]. Onset in familial PCa is 
usually reported in men under 55 years old however, sporadic PCa rarely diagnose at this age [90]. From all 
cases approximately 10% have been reported as familial PCa whereas approximately 40% of patients under 55 
years old account for familial PCa. The two most important genes ; BRCA1 and BRCA2, which are responsible 
for breast cancer , are associated with high risk of PCa  in men under 65 years old [91].  
Current recommended normal reference range for PSA is 0-4.0 ng/ml. However efforts to increase the 
sensitivity of cancer detection in younger men and decrease the number of unnecessary biopsies in older men 
(improve specificity) led to establishing age and race specific PSA range suggested recommendations have been 
developed based of the results of several researches that demonstrated the PSA levels correlation with patient’s 
race, age and prostate volume (Table 1) [30]. Since the use of PSA is limited and controversial, the search for 
novel PCa-specific biomarkers, especially from non-invasive bio-fluids is an important task [92]. Due to the 
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heterogeneity of the disease, no single biomarker will be diagnostic and prognostic for every patient [93]. Based 
on this, it can be concluded that the next diagnosis or PSA test will most likely be an assay comprising multiple 
biomarkers that are differentially expressed in PCa. Also, success of these biomarkers will depend on their 
validation in large cohort of patients and translation of these findings to clinical practice. 
 
5. Comparative NGS analyses of PCa datasets: 
There has been a consistent need to understand the genetics behind PCa although a large number of 
cohort studies have been instrumental in identifying the causal genes and differentially expressed genes (DEG). 
From our pilot analyses, we surveyed four datasets (supplementary table 1) across Caucasians, American and 
Asian (Chinese) [94–96] and tried to predict the common genes across them (figure 3). This gives a subtle 
reason to demonstrate the effect of DEGs and the nature of the genes observed from transcriptome and whole 
exome sequencing (WES) respectively (supplementary information). While comparing exomes between 
Caucasian and Asian population, we observed eleven common genes between them, viz. ITGA7, ZNF691, 
ZSWIM5, NRG4, KRBA2, ECT2, FAM91A1, PDZD8, PYGL, EDN2 and TP53I3. On the other hand, CRISP, 
CSRP3, COL2A1, UGT1A6, UGT1A1, LRRN1, UGT1A3, B4GALNT4 and KCNC2, a total of nine genes were 
common between transcriptome of Caucasian and Asians, and we observed eight common genes in between 
"DEGs", "Exome Caucasian" and "Exome Asian" in the form of ITGA7, ZNF691, ZSWIM5, NRG4, KRBA2, 
FAM91A1, PDZD8, PYGL and three common between the DEGs and exome Caucasian, IGDCC4, LIG4 and 
EZH2.   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.3
a 
Figure.3b 
Figure.3c 
   ISSN: 2278-8115 
IJCB Vol. 8, No. 1, Oct 2019, 09 – 20      http://www.ijcb.in 
Figure 3.(a) The Venn diagram shows eleven common genes across Caucasian and Asian exome 
datasets (ITGA7, ZNF691, ZSWIM5, NRG4, KRBA2, ECT2, FAM91A1, PDZD8, PYGL EDN2 andTP53I3). (b) 
Nine common genes in Caucasian and Asian transcriptome (CRISP3, CSRP3, COL2A1, UGT1A6, UGT1A1, 
LRRN1, UGT1A3, B4GALNT4, KCNC2) out of total 3169 genes from Asian dataset and 105 genes from the 
Caucasian dataset and (c) Eight common genes (ITGA7, ZNF691, ZSWIM5, NRG4, KRBA2, FAM91A1, PDZD8, 
PYGL) across Asian exome, Caucasian exome and DEGs were found. However, three common genes (IGDCC4, 
EZH2, and LIG4) were found across DEGs and Caucasian exome. 
 
 
6. Palliative Care 
Palliative care is specialized medical care that is catered for serious illness. While it focuses on 
providing relief from the symptoms, pain and stress, several attempts have been made to improve quality of life 
for the patient and family members [97,98]. PCa leads to various problems such as interrupted flow of urine, 
difficulty starting or stopping urination and painful or burning sensation during urination. Other symptoms 
might include pain in bones, lower back, hips or upper thighs; difficulty having an erection; pain with 
ejaculation; and blood in the urine or semen. Early PCa, however, does not usually cause such extreme 
symptoms. Several options for treating PCa include surgery, radiation therapy and hormone therapy [99]. 
Abiraterone acetate is a type of hormone therapy given to patients with metastatic PCa when they stop 
responding to other types of hormone therapy as the drug stops the testosterone production. [100]. The survival 
however, for post-palliative care is assumed to be nine to twelve months. 
 
 
7. Conclusions 
Cancer prostate is alarming and considered third most significant cancers in Asia alone. There is an 
increase in prevalence and incidences in India which begs us a question whether any specific mutations are 
characteristics for Indian phenotype. This could ideally in purview of the fact that the diet and lifestyle 
conditions are different to that of west. In this review, while providing a summary of causative genes 
responsible for various diseases, we have attempted to discuss the reasons pertaining to the lack of PCa 
diagnoses in Indian population while reviewing the challenges, methods and histopathological aspects of PCa. 
However, one definitive need for post treatment regimen is palliative care which is certainly lacking with PCa 
diagnoses. With the NGS datasets uprising, one question still remains elusive:  Is there an end to the problems of 
early detection of PCa? 
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